Antibody data
- Antibody Data
- Antigen structure
- References [37]
- Comments [0]
- Validations
- Western blot [2]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- HPA008736 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#HPA008736, RRID:AB_1078625
- Product name
- Anti-DAXX
- Antibody type
- Polyclonal
- Description
- Polyclonal Antibody against Human DAXX, Gene description: death-domain associated protein, Alternative Gene Names: DAP6, Validated applications: IHC, WB, Uniprot ID: Q9UER7, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 µl
- Concentration
- 0.1 mg/ml
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Handling
- The antibody solution should be gently mixed before use.
Submitted references Patient derived tumoroids of high grade neuroendocrine neoplasms for more personalized therapies
DAXX adds a de novo H3.3K9me3 deposition pathway to the histone chaperone network
Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size
Immunohistochemical analyses of the expression profiles of INSM1, ATRX, DAXX and DLL3 in solid papillary carcinomas of the breast
Enhancer of Zeste Homolog 2 (EZH2) Is a Marker of High-Grade Neuroendocrine Neoplasia in Gastroenteropancreatic and Pulmonary Tract and Predicts Poor Prognosis
TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT
DNAJC9 integrates heat shock molecular chaperones into the histone chaperone network
Death domain-associated protein (DAXX) expression is associated with poor survival in metastatic high-grade serous carcinoma
Telomere length alterations and ATRX/DAXX loss in pituitary adenomas
Alternative Lengthening of Telomeres and Differential Expression of Endocrine Transcription Factors Distinguish Metastatic and Non-metastatic Insulinomas
Telomere alterations in neurofibromatosis type 1-associated solid tumors
Functional Loss of ATRX and TERC Activates Alternative Lengthening of Telomeres (ALT) in LAPC4 Prostate Cancer Cells
A Comparison of Death Domain-Associated Protein 6 in Different Endometrial Carcinomas Histotypes
Importance of Promyelocytic Leukema Protein (PML) for Kaposi’s Sarcoma-Associated Herpesvirus Lytic Replication
A unique telomere DNA expansion phenotype in human retinal rod photoreceptors associated with aging and disease
Alternative lengthening of telomeres, ATRX loss and H3‐K27M mutations in histologically defined pilocytic astrocytoma with anaplasia
Grading of Neuroendocrine Carcinomas: Correlation of 68Ga-PET/CT Scan with Tissue Biomarkers
ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner
DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors
Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival
Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors
Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors
Daxx inhibits hypoxia-induced lung cancer cell metastasis by suppressing the HIF-1α/HDAC1/Slug axis
TERT promoter mutations in pancreatic endocrine tumours are rare and mainly found in tumours from patients with hereditary syndromes
Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12
ATRX represses alternative lengthening of telomeres
Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas
Epigenetic dysregulation and poorer prognosis in DAXX-deficient pancreatic neuroendocrine tumours
TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast
Loss of ATRX and DAXX expression identifies poor prognosis for smooth muscle tumours of uncertain malignant potential and early stage uterine leiomyosarcoma
TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast
ATRX represses alternative lengthening of telomeres
Sp100 Provides Intrinsic Immunity against Human Papillomavirus Infection
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors
Altered Telomeres in Tumors with ATRX and DAXX Mutations
April-Monn S, Kirchner P, Detjen K, Bräutigam K, Trippel M, Grob T, Statzer C, Maire R, Kollàr A, Chouchane A, Kunze C, Horst D, Sadowski M, Schrader J, Marinoni I, Wiedenmann B, Perren A
npj Precision Oncology 2024;8(1)
npj Precision Oncology 2024;8(1)
DAXX adds a de novo H3.3K9me3 deposition pathway to the histone chaperone network
Carraro M, Hendriks I, Hammond C, Solis-Mezarino V, Völker-Albert M, Elsborg J, Weisser M, Spanos C, Montoya G, Rappsilber J, Imhof A, Nielsen M, Groth A
Molecular Cell 2023;83(7):1075-1092.e9
Molecular Cell 2023;83(7):1075-1092.e9
Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size
Hackeng W, Brosens L, Kim J, O'Sullivan R, Sung Y, Liu T, Cao D, Heayn M, Brosnan-Cashman J, An S, Morsink F, Heidsma C, Valk G, Vriens M, Nieveen van Dijkum E, Offerhaus G, Dreijerink K, Zeh H, Zureikat A, Hogg M, Lee K, Geller D, Marsh J, Paniccia A, Ongchin M, Pingpank J, Bahary N, Aijazi M, Brand R, Chennat J, Das R, Fasanella K, Khalid A, McGrath K, Sarkaria S, Singh H, Slivka A, Nalesnik M, Han X, Nikiforova M, Lawlor R, Mafficini A, Rusev B, Corbo V, Luchini C, Bersani S, Pea A, Cingarlini S, Landoni L, Salvia R, Milione M, Milella M, Scarpa A, Hong S, Heaphy C, Singhi A
Gut 2022;71(5):961-973
Gut 2022;71(5):961-973
Immunohistochemical analyses of the expression profiles of INSM1, ATRX, DAXX and DLL3 in solid papillary carcinomas of the breast
Yanai H, Ishida M, Yoshikawa K, Tsuta K, Sekimoto M, Sugie T
Oncology Letters 2022;23(4)
Oncology Letters 2022;23(4)
Enhancer of Zeste Homolog 2 (EZH2) Is a Marker of High-Grade Neuroendocrine Neoplasia in Gastroenteropancreatic and Pulmonary Tract and Predicts Poor Prognosis
Bremer S, Bittner G, Elakad O, Dinter H, Gaedcke J, König A, Amanzada A, Ellenrieder V, Freiherr von Hammerstein-Equord A, Ströbel P, Bohnenberger H
Cancers 2022;14(12):2828
Cancers 2022;14(12):2828
TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT
de Nonneville A, Salas S, Bertucci F, Sobinoff A, Adélaïde J, Guille A, Finetti P, Noble J, Churikov D, Chaffanet M, Lavit E, Pickett H, Bouvier C, Birnbaum D, Reddel R, Géli V
EMBO Molecular Medicine 2022;14(10)
EMBO Molecular Medicine 2022;14(10)
DNAJC9 integrates heat shock molecular chaperones into the histone chaperone network
Hammond C, Bao H, Hendriks I, Carraro M, García-Nieto A, Liu Y, Reverón-Gómez N, Spanos C, Chen L, Rappsilber J, Nielsen M, Patel D, Huang H, Groth A
Molecular Cell 2021;81(12):2533-2548.e9
Molecular Cell 2021;81(12):2533-2548.e9
Death domain-associated protein (DAXX) expression is associated with poor survival in metastatic high-grade serous carcinoma
Davidson B, McFadden E, Holth A, Brunetti M, Flørenes V
Virchows Archiv 2020;477(6):857-864
Virchows Archiv 2020;477(6):857-864
Telomere length alterations and ATRX/DAXX loss in pituitary adenomas
Heaphy C, Bi W, Coy S, Davis C, Gallia G, Santagata S, Rodriguez F
Modern Pathology 2020;33(8):1475-1481
Modern Pathology 2020;33(8):1475-1481
Alternative Lengthening of Telomeres and Differential Expression of Endocrine Transcription Factors Distinguish Metastatic and Non-metastatic Insulinomas
Hackeng W, Schelhaas W, Morsink F, Heidsma C, van Eeden S, Valk G, Vriens M, Heaphy C, Nieveen van Dijkum E, Offerhaus G, Dreijerink K, Brosens L
Endocrine Pathology 2020;31(2):108-118
Endocrine Pathology 2020;31(2):108-118
Telomere alterations in neurofibromatosis type 1-associated solid tumors
Rodriguez F, Graham M, Brosnan-Cashman J, Barber J, Davis C, Vizcaino M, Palsgrove D, Giannini C, Pekmezci M, Dahiya S, Gokden M, Noë M, Wood L, Pratilas C, Morris C, Belzberg A, Blakeley J, Heaphy C
Acta Neuropathologica Communications 2019;7(1)
Acta Neuropathologica Communications 2019;7(1)
Functional Loss of ATRX and TERC Activates Alternative Lengthening of Telomeres (ALT) in LAPC4 Prostate Cancer Cells
Graham M, Kim J, Da J, Brosnan-Cashman J, Rizzo A, Baena Del Valle J, Chia L, Rubenstein M, Davis C, Zheng Q, Cope L, Considine M, Haffner M, De Marzo A, Meeker A, Heaphy C
Molecular Cancer Research 2019;17(12):2480-2491
Molecular Cancer Research 2019;17(12):2480-2491
A Comparison of Death Domain-Associated Protein 6 in Different Endometrial Carcinomas Histotypes
Jin C, Hacking S, Komforti M, Nasim M
Biomarker Insights 2019;14
Biomarker Insights 2019;14
Importance of Promyelocytic Leukema Protein (PML) for Kaposi’s Sarcoma-Associated Herpesvirus Lytic Replication
Hossain M, Ohsaki E, Honda T, Ueda K
Frontiers in Microbiology 2018;9
Frontiers in Microbiology 2018;9
A unique telomere DNA expansion phenotype in human retinal rod photoreceptors associated with aging and disease
Bell W, Meeker A, Rizzo A, Rajpara S, Rosenthal I, Flores Bellver M, Aparicio Domingo S, Zhong X, Barber J, Joshu C, Canto‐Soler M, Eberhart C, Heaphy C
Brain Pathology 2018;29(1):45-52
Brain Pathology 2018;29(1):45-52
Alternative lengthening of telomeres, ATRX loss and H3‐K27M mutations in histologically defined pilocytic astrocytoma with anaplasia
Rodriguez F, Brosnan‐Cashman J, Allen S, Vizcaino M, Giannini C, Camelo‐Piragua S, Webb M, Matsushita M, Wadhwani N, Tabbarah A, Hamideh D, Jiang L, Chen L, Arvanitis L, Alnajar H, Barber J, Rodríguez‐Velasco A, Orr B, Heaphy C
Brain Pathology 2018;29(1):126-140
Brain Pathology 2018;29(1):126-140
Grading of Neuroendocrine Carcinomas: Correlation of 68Ga-PET/CT Scan with Tissue Biomarkers
Liverani C, Bongiovanni A, Mercatali L, Foca F, Pieri F, De Vita A, Spadazzi C, Miserocchi G, Recine F, Riva N, Nicolini S, Severi S, Martinelli G, Ibrahim T
Disease Markers 2018;2018
Disease Markers 2018;2018
ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner
Ouellette M, Brosnan-Cashman J, Yuan M, Graham M, Rizzo A, Myers K, Davis C, Zhang R, Esopi D, Raabe E, Eberhart C, Heaphy C, Meeker A
PLOS ONE 2018;13(9):e0204159
PLOS ONE 2018;13(9):e0204159
DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors
Park J, Paik W, Lee K, Ryu J, Lee S, Kim Y
Oncotarget 2017;8(30):49796-49806
Oncotarget 2017;8(30):49796-49806
Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
Mohamed A, Romano D, Saveanu A, Roche C, Albertelli M, Barbieri F, Brue T, Niccoli P, Delpero J, Garcia S, Ferone D, Florio T, Moutardier V, Poizat F, Barlier A, Gerard C
Oncotarget 2017;8(25):41044-41063
Oncotarget 2017;8(25):41044-41063
Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival
Kim J, Brosnan-Cashman J, An S, Kim S, Song K, Kim M, Kim M, Hwang D, Meeker A, Yu E, Kim S, Hruban R, Heaphy C, Hong S
Clinical Cancer Research 2017;23(6):1598-1606
Clinical Cancer Research 2017;23(6):1598-1606
Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors
Singhi A, Liu T, Roncaioli J, Cao D, Zeh H, Zureikat A, Tsung A, Marsh J, Lee K, Hogg M, Bahary N, Brand R, McGrath K, Slivka A, Cressman K, Fuhrer K, O'Sullivan R
Clinical Cancer Research 2017;23(2):600-609
Clinical Cancer Research 2017;23(2):600-609
Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors
VandenBussche C, Allison D, Graham M, Charu V, Lennon A, Wolfgang C, Hruban R, Heaphy C
Cancer Cytopathology 2017;125(7):544-551
Cancer Cytopathology 2017;125(7):544-551
Daxx inhibits hypoxia-induced lung cancer cell metastasis by suppressing the HIF-1α/HDAC1/Slug axis
Lin C, Wang L, Wang S, Chang Y, Wu Y, Chen H, Hsiao T, Lai W, Lu H, Chang Y, Yang S, Lin M, Chen C, Hong T, Yang P
Nature Communications 2016;7(1)
Nature Communications 2016;7(1)
TERT promoter mutations in pancreatic endocrine tumours are rare and mainly found in tumours from patients with hereditary syndromes
Vinagre J, Nabais J, Pinheiro J, Batista R, Oliveira R, Gonçalves A, Pestana A, Reis M, Mesquita B, Pinto V, Lyra J, Cipriano M, Ferreira M, Lopes J, Sobrinho-Simões M, Soares P
Scientific Reports 2016;6(1)
Scientific Reports 2016;6(1)
Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12
Morton C, Mäkinen N, Aavikko M, Heikkinen T, Taipale M, Taipale J, Koivisto-Korander R, Bützow R, Vahteristo P
PLOS Genetics 2016;12(2):e1005850
PLOS Genetics 2016;12(2):e1005850
ATRX represses alternative lengthening of telomeres
Napier C, Huschtscha L, Harvey A, Bower K, Noble J, Hendrickson E, Reddel R
Oncotarget 2015;6(18):16543-16558
Oncotarget 2015;6(18):16543-16558
Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas
Fishbein L, Khare S, Wubbenhorst B, DeSloover D, D’Andrea K, Merrill S, Cho N, Greenberg R, Else T, Montone K, LiVolsi V, Fraker D, Daber R, Cohen D, Nathanson K
Nature Communications 2015;6(1)
Nature Communications 2015;6(1)
Epigenetic dysregulation and poorer prognosis in DAXX-deficient pancreatic neuroendocrine tumours
Pipinikas C, Dibra H, Karpathakis A, Feber A, Novelli M, Oukrif D, Fusai G, Valente R, Caplin M, Meyer T, Teschendorff A, Bell C, Morris T, Salomoni P, Luong T, Davidson B, Beck S, Thirlwell C
Endocrine-Related Cancer 2015;22(3):L13-L18
Endocrine-Related Cancer 2015;22(3):L13-L18
TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast
Yoshida M, Ogawa R, Yoshida H, Maeshima A, Kanai Y, Kinoshita T, Hiraoka N, Sekine S
British Journal of Cancer 2015;113(8):1244-1248
British Journal of Cancer 2015;113(8):1244-1248
Loss of ATRX and DAXX expression identifies poor prognosis for smooth muscle tumours of uncertain malignant potential and early stage uterine leiomyosarcoma
Slatter T, Hsia H, Samaranayaka A, Sykes P, Clow W, Devenish C, Sutton T, Royds J, PC P, Cheung A, Hung N
The Journal of Pathology: Clinical Research 2015;1(2):95-105
The Journal of Pathology: Clinical Research 2015;1(2):95-105
TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast
Yoshida M, Ogawa R, Yoshida H, Maeshima A, Kanai Y, Kinoshita T, Hiraoka N, Sekine S
British Journal of Cancer 2015 September;113(8):1244-1248
British Journal of Cancer 2015 September;113(8):1244-1248
ATRX represses alternative lengthening of telomeres
Napier C, Huschtscha L, Harvey A, Bower K, Noble J, Hendrickson E, Reddel R
Oncotarget 2015 June;6(18):16543-16558
Oncotarget 2015 June;6(18):16543-16558
Sp100 Provides Intrinsic Immunity against Human Papillomavirus Infection
Stepp W, Meyers J, McBride A, Imperiale M
mBio 2013;4(6)
mBio 2013;4(6)
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
Schwartzentruber J, Korshunov A, Liu X, Jones D, Pfaff E, Jacob K, Sturm D, Fontebasso A, Quang D, Tönjes M, Hovestadt V, Albrecht S, Kool M, Nantel A, Konermann C, Lindroth A, Jäger N, Rausch T, Ryzhova M, Korbel J, Hielscher T, Hauser P, Garami M, Klekner A, Bognar L, Ebinger M, Schuhmann M, Scheurlen W, Pekrun A, Frühwald M, Roggendorf W, Kramm C, Dürken M, Atkinson J, Lepage P, Montpetit A, Zakrzewska M, Zakrzewski K, Liberski P, Dong Z, Siegel P, Kulozik A, Zapatka M, Guha A, Malkin D, Felsberg J, Reifenberger G, von Deimling A, Ichimura K, Collins V, Witt H, Milde T, Witt O, Zhang C, Castelo-Branco P, Lichter P, Faury D, Tabori U, Plass C, Majewski J, Pfister S, Jabado N
Nature 2012;482(7384):226-231
Nature 2012;482(7384):226-231
Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors
de Wilde R, Heaphy C, Maitra A, Meeker A, Edil B, Wolfgang C, Ellison T, Schulick R, Molenaar I, Valk G, Vriens M, Borel Rinkes I, Offerhaus G, Hruban R, Matsukuma K
Modern Pathology 2012;25(7):1033-1039
Modern Pathology 2012;25(7):1033-1039
Altered Telomeres in Tumors with ATRX and DAXX Mutations
Heaphy C, de Wilde R, Jiao Y, Klein A, Edil B, Shi C, Bettegowda C, Rodriguez F, Eberhart C, Hebbar S, Offerhaus G, McLendon R, Rasheed B, He Y, Yan H, Bigner D, Oba-Shinjo S, Marie S, Riggins G, Kinzler K, Vogelstein B, Hruban R, Maitra A, Papadopoulos N, Meeker A
Science 2011;333(6041):425-425
Science 2011;333(6041):425-425
No comments: Submit comment
Enhanced validation
- Submitted by
- Atlas Antibodies (provider)
- Enhanced method
- Genetic validation
- Main image
- Experimental details
- Western blot analysis in HEK293 cells transfected with control siRNA, target specific siRNA probe #1 and #2, using Anti-DAXX antibody. Remaining relative intensity is presented. Loading control: Anti-GAPDH.
- Sample type
- Human
- Protocol
- Protocol
- Submitted by
- Atlas Antibodies (provider)
- Enhanced method
- Recombinant expression validation
- Main image
- Experimental details
- Western blot analysis in control (vector only transfected HEK293T lysate) and DAXX over-expression lysate (Co-expressed with a C-terminal myc-DDK tag (~3.1 kDa) in mammalian HEK293T cells, LY427987).
- Sample type
- Human
- Protocol
- Protocol
Supportive validation
- Submitted by
- Atlas Antibodies (provider)
- Enhanced method
- Orthogonal validation
- Main image
- Experimental details
- Immunohistochemistry analysis in human testis and skeletal muscle tissues using HPA008736 antibody. Corresponding DAXX RNA-seq data are presented for the same tissues.
- Sample type
- Human
- Protocol
- Protocol